



ACR Convergence 2025

October 24–29, 2025
Chicago, United States



TOP ABSTRACTS

To help navigate the exciting content being presented at the American College of Rheumatology (ACR) Convergence 2025, the Lupus Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lupus.

ACR 2025: Top abstracts in lupus

October 24–29, 2025

Oral presentations: Sunday, October 26

#	Title	Presenter	Time (CDT)
0801 View	Achieving sustained lupus low disease activity state and remission with Ianalumab (VAY736) in patients with systemic lupus erythematosus: A post hoc analysis from a phase II study	Ed Vital	13:00–13:15
0802 View	Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: Pooled post-hoc exploratory analysis from a randomized placebo-controlled phase II study	Eric Morand	13:15–13:30
0803 View	Improved efficacy and safety outcomes in patients with SLE treated with belimumab (BEL) versus immunosuppressants (IS), in addition to antimalarials (AM) and glucocorticoids (GC): A post hoc summary of five phase 3 trials	Mariele Gatto	13:30–13:45

Oral presentations: Wednesday, October 29

#	Title	Presenter	Time (CDT)
2650 View	LFA-REAL outperforms SLEDAI and BILAG in detecting clinical change in lupus activity	Alberto Nordmann-Gomes	10:45–11:00
2694 View	Effect of deucravacitinib treatment on renal dysfunction-associated plasma biomarkers from a phase 2 study in patients with systemic lupus erythematosus	Amit Saxena	11:45–12:00
2696 View	Biomarker data from an open-label, phase 1/2 study for YTB323 (rapcabbitagene autoleucel, a rapidly manufactured CD19 CAR-T therapy) suggest reset of the B cell compartment in severe refractory SLE	Eric Morand	12:15–12:30

Posters			
#	Title	Presenter	Date and time (CDT)
0640 View	Impact of clinically important improvements in patient-reported outcomes on disease activity in patients with systemic lupus erythematosus treated with upadacitinib or placebo: Results from the phase 2 SLEek study	Vibeke Strand	Sunday, October 26, 10:30–12:30
0645 View	Achievement of low disease activity and remission in patients with systemic lupus erythematosus treated with dapirolizumab pegol: 48-week results from a phase 3 trial	Eric Morand	Sunday, October 26, 10:30–12:30
0650 View	Obinutuzumab demonstrates steroid-sparing effects and consistent benefit in patients with lupus nephritis when using multiple primary endpoint definitions: A secondary analysis of phase III trial results	Brad Rovin	Sunday, October 26, 10:30–12:30
1519 View	Post-hoc analysis of sustained response over time in systemic lupus erythematosus patients treated with cenerimod in CARE (phase 2 B) study	Anca Askanase	Monday, October 27, 10:30–12:30
1529 View	Updated phase 1 trial data assessing the tolerability, efficacy, pharmacokinetics, and pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed chimeric antigen receptor t cell therapy using a next-generation process for severe, refractory SLE	Georg Schett	Monday, October 27, 10:30–12:30
1532 View	Preliminary safety, efficacy, and cellular kinetics of CTA313, a CD19/BCMA dual-targeted universal CAR-T therapy, for active systemic lupus erythematosus	Jan Davidson-Moncada	Monday, October 27, 10:30–12:30
1545 View	Efficacy and safety of subcutaneous anifrolumab in systemic lupus erythematosus: Interim analysis of a phase 3 randomized placebo-controlled study	Susan Manzi	Monday, October 27, 10:30–12:30
2445 View	Achievement of treat to target measures with upadacitinib in patients with systemic lupus erythematosus: Phase 2 randomized sleek clinical trial results	Eric Morand	Tuesday, October 28, 10:30–12:30
2458 View	Obecabtagene autoleucel (obe-cel), a CD19-targeting autologous chimeric antigen receptor T-cell therapy (CAR T) with a fast off-rate binding domain, in patients (pts) with severe, refractory systemic lupus erythematosus (srSLE): Preliminary results from the phase I CARLYSLE study	Maria Leandro	Tuesday, October 28, 10:30–12:30

Posters (continued)			
#	Title	Presenter	Date and time (CDT)
2464 View	IMC-002 (IMM0306), a first-in-class bi-specific fusion protein, demonstrates improvements in systemic lupus erythematosus (SLE) disease activity measures and biomarkers in patients with moderate to severe active SLE in the Open-label phase 1b/2 study	Qian Zheng	Tuesday, October 28, 10:30–12:30
2465 View	CD19/BCMA dual-targeting FasTCAR-T cells GC012F (AZD0120) in patients with refractory systemic lupus erythematosus: An open-label, single-center phase I study	Qiong Fu	Tuesday, October 28, 10:30–12:30
2466 View	Efficacy and safety results of zetomipzomib from the PALIZADE phase 2b clinical trial in patients with lupus nephritis	Richard A. Furie	Tuesday, October 28, 10:30–12:30
2468 View	RESET-SLE: Clinical trial evaluating rese-cel (Resecabtagene Autoleucel), a fully human, autologous 4-1BB CD19-CAR T cell therapy in non-renal SLE and lupus nephritis	Saira Sheikh	Tuesday, October 28, 10:30–12:30
LB10 View	Four-year safety and efficacy of deucravacitinib in systemic lupus erythematosus: Results from a phase 2 program	Eric Morand	Tuesday, October 28, 10:30–12:30
LB13 View	Obinutuzumab leads to deep B-cell depletion in the kidney parenchyma of patients with lupus nephritis: An exploratory analysis of the REGENCY trial	Brad H. Rovin	Tuesday, October 28, 10:30–12:30



ACR 2025

Follow us on X to keep up to date
with the latest from the congress

@lupus_hub



Brought to you by

